PRNewsWire
28 Sept 2025, 14:00 UTC · 51w ago
Verdict
Headline takes no side. We score AXGN −1.00 across two claims — strongly bearish.
−1.00strongly bearish
More negative than 97% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
The FDA extended the PDUFA goal date for Axogen's Avance Nerve Graft BLA by three months to December 5, 2025.
More negative than 93% of claims this week
Pomerantz LLP is investigating whether Axogen and its officers engaged in securities fraud or unlawful business practices.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 84% of claims this week
Which stocks this story touches
More negative than 97% of ticker scores this week
The company is facing a securities fraud investigation by a law firm following an FDA delay and a significant stock price drop.
More negative than 97% of ticker scores this week
The company is the subject of an investor claims investigation by the Pomerantz Law Firm.
More negative than 97% of ticker scores this week
The company is the subject of an investor claims investigation by the Pomerantz Law Firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
54m ago
+157.8%
Price is moving against the score
$44.23 vs $17.16 close before publication (Sep 26) · not market-adjusted
AXGN chart →
